TABLE 3.
Activities of FIV HR2 peptides against HIV-1 and HIV HR2 peptides against FIVa
| Target virus | Peptide | EC50 (μM) | EC90 (μM) |
|---|---|---|---|
| HIV-1 | T1569 | >2.365 | >2.365 |
| T1577 | 1.933 | >2.342 | |
| T1967 | 2.053 | >2.518 | |
| T1968 | >2.473 | >2.473 | |
| T1971 | >2.342 | >2.342 | |
| T1972 | >2.304 | >2.304 | |
| T1988 | >2.322 | >2.322 | |
| T1989 | >2.321 | >2.321 | |
| FIV | T20 | 17.587 | >22.262 |
| T649 | >22.070 | >22.070 |
a
EC50s for FIV HR2 peptides in the HIV fusion assay and for HIV HR2 peptides in the FIV syncytial plaque-forming assay. The EC50s for each peptide were determined using the Karber method. The most active peptides are boldfaced.